Lifeboat Foundation

A major concerned for Lockheed is the long passage of time between the crew’s training and the moment a serious issue does come up during a mission—which could be a few years later. “They may not remember the training. Having the right kind of on-board documentation and flight computer to be able to provide the astronauts the information they need when they need it, is important,” Pratt said. “Not just having the alarm go off but having the alarm go off and the PDF file of the manual come up at the same time. That’s really useful in helping the crew understand how to operate their own vehicle.”

Even though Lockheed Martin’s early habitat concept will service exploration missions near the Moon, the company is always thinking about the manned mission to Mars, which will require a far more advanced successor to their current designs. Engineers will need to go through a few iterations of the concept after the health effects of long-duration human spaceflight are known and as new technology is developed. This is the basis that NASA created NextSTEP on.

The federal space agency is looking for a modular habitat that can grow, evolve and be added to. “New modules are built upon the lessons of the previous modules,” Hopkins said.

Continue reading “With Mars in Mind, Lockheed Martin Designs Human Habitat to Orbit Moon” »

Very cool.

For more than a decade, biomedical researchers have been looking for better ways to deliver cancer-killing medication directly to tumors in the body. Tiny capsules, called nanoparticles, are now being used to transport chemotherapy medicine through the bloodstream, to the doorstep of cancerous tumors. But figuring out the best way for the particles to get past the tumor’s “velvet rope” and enter the tumor is a challenge scientists are still working out. Drexel University researchers believe that the trick to gaining access to the pernicious cellular masses is to give the nanoparticles a new look—and that dressing to impress will be able to get them past the tumor’s biological bouncers.

Targeted cancer therapy is most effective when the medication is released as close as possible to the interior of a tumor, to increase its odds of penetrating and killing off cancerous cells. The challenge that has faced cancer researchers for years is making a delivery vehicle that is sturdy enough to safely get the medication through the bloodstream to tumors—which is no smooth ride—but is also lithe enough to squeeze through the tumor’s dense extra cellular space—a matrix stuffed with sugars called hyaluronic acid.

Continue reading “Dressed to kill: Tailoring a suit for tumor-penetrating cancer meds” »

Nanomedicine has been something that many in tech expected to be a critical part of the healthcare landscape for over a decade. I am glad to see how quickly the technology is being adopted as part of bio-medical research and treatments for various diseases, etc.

NEW YORK, April 7, 2016 /PRNewswire/ — Nano-based science paving the precision medicine era.

The continued development of new treatments associated with the demographic trends and public health considerations is remarkable. Nanotechnology has been identified as one most relevant key enabling technologies of the last ten years, significantly impacting on many different biomedical developments in a broad spectrum of applications therapeutics, diagnostics, theranostics, medical imaging, regenerative medicine, life sciences research and biosciences, among many others. In fact, nanomedicine is present in all therapeutic areas, exhibiting a perceptible and extensive impact in the treatment and diagnosis of some most concerned diseases.

Continue reading “Trends in Nanomedicine — Technology Benchmarking & Innovator Analysis” »

Zika. Ebola. Dengue. Influenza. Chikungunya. These are but a few among the growing cadre of viruses that today pose serious health threats to U.S. troops, as well as to civilian populations in the United States and around the world. Vaccines exist for but a few of these infectious diseases. And since these viruses have an uncanny ability to mutate and morph as they reproduce inside their hosts, those few vaccines that do exist are quickly outdated, providing little protection against the latest viral strains. That’s why flu vaccine manufacturers, for example, must produce new versions annually, at enormous expense and with variable year-to-year efficacy.

Ideally, to outpace evolving pathogens, a therapy or a vaccine would adapt in real time, shape-shifting as fast as its targets do. To pursue that radical approach, DARPA today launched its INTERfering and Co-Evolving Prevention and Therapy (INTERCEPT) program.

“We need a new paradigm to stay ahead of these moving targets,” said Jim Gimlett, DARPA program manager. “With INTERCEPT, the goal is to develop viral therapies that are effective against a broad spectrum of viral strains, and that can co-evolve and outpace new strains.”

A common drug could hold the key to long life, in flies at least, according to research.

At low doses, lithium prolonged the life of fruit flies in lab experiments.

Scientists say the finding is “encouraging” and could eventually lead to new drugs to help people live longer and healthier lives.

A new programming language allows scientists to custom-code bacteria that can measure the health of other cells, and administer drugs when necessary.

Very nice goal to have “all things connected” in Toyota’s and Microsoft’s case is “Singularity” lite meaning physical structures are connected; however, bio connection does not exist (only consumer profile information is available and integrated). This could be considered an interim state for Singularity.

The company called Toyota Connected has a goal of simplifying technology so it’s easier to use, perhaps even getting rid of distracting and complicated touch screens that now are in most cars and replacing them with heads-up or voice-activated technology, said Zack Hicks, the company’s CEO who also is Toyota Motor America’s chief information officer. Like other automakers, Toyota Connected will research connecting cars to each other and to homes, as well as telematics features that learn and anticipate a driver’s habits. The company, like other automakers, will explore transmitting a driver’s health data to a doctor or driving patterns to an insurance company so people are insured based on where they travel, Toyota said.

Scientists just got one step closer to understanding the nuts and bolts of how your mind handles emotions. An MIT team has identified two neural connections in the brain’s amygdala regions that process positive and negative emotional events. By tagging neuron groups with a light-sensitive protein, they discovered that the neurons form parallel but complex channels that respond differently to given situations. Some neurons within one of those connection will be excited by a feeling, while others will be inhibited — the combination of those reactions in a given channel may determine the emotion you experience.

It’s still early days. The researchers need to explore specific neuron populations in-depth to see how they’re connected, and they have to clearly define the larger neural circuits. If they succeed, though, they might help explain how mental health issues operate. Anxiety and depression might not fire the neurons that normally go off when you’re happy, for instance. The discoveries could lead to more effective treatments that restore your natural reactions.

Continue reading “Scientists identify neurons that help you process emotions” »

1st of many steps in the gene editing oversight.

PRINCETON, N.J., March 29, 2016 /PRNewswire/ — WIRB-Copernicus Group^® (WCG™), one of the world’s leading providers of solutions that measurably improve the quality and efficiency of clinical research, today announced that it has assembled a team of world-renowned experts to advise the company regarding the latest advances in gene therapy research. The WCG Gene Therapy™ Advisory Board will convene today in Princeton, NJ.

“Human gene therapy is one of the fastest-growing areas of medical research, and also one of the most promising,” said WCG Chairman and Chief Executive Officer Donald A. Deieso, Ph.D. “The advances made by scientists and clinicians in the field of gene therapy have enabled us to target disease at the genetic level, redefining the concept of precision medicine.” He added, “More than that, gene transfer researchers have succeeded – over the course of a single lifetime – in transforming the world’s most persistent and lethal viruses into disease-fighting allies in the quest to improve human health.”

Continue reading “WIRB-Copernicus Group Establishes WCG Gene Therapy Advisory Board” »